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CLINICAL CASE SEMINAR 
Greetings from Below the Aortic Arch! The Paradigm of 
Cardiac Paraganglioma 
ARMIN E. HEUFELDER AND LORENZ C. HOFBAUER 
Medizinische Klinik, Klinikum Innenstadt, Ludwig-Maximilians-Uniuersittit, 80336 Miinchen, 
Germany 
A 42-yr-old female, mother of five children, was referred to this institution for further evaluation of recurrent 
episodes of severe arterial hypertension. Blood pressures 
taken on several occasions during the past 3 yr by her general 
practitioner had documented recurrent hypertensive crises 
with systolic/diastolic measurements of up to 300/145 mm 
Hg. These episodes were frequently accompanied by head- 
ache, palpitations, sweating, nausea, and pallor followed by 
weakness. Her past medical history was remarkable only for 
transient hepatitis B following blood transfusion in 1970 and 
Cesarian section in 1986. Family history was negative for 
multiple endocrine neoplasia (MEN) type 2A and 2B syn- 
dromes, von Recklinghausen’s neurofibromatosis, and von 
Hippel-Lindau’s disease. Her medications included inter- 
mittent usage of furosemide (40 mg/day) for leg edema and 
L-thyroxine (200 pg/day) for a history of hypothyroidism. 
Diagnostic tests before referral had revealed an elevated 24-h 
urinary excretion of vanillylmandelic acid at 27 mg/24 h 
(0.3-7.7 mg/24 h) and normal 24-h urinary excretion of cat- 
echolamines. In addition, on computed tomography of the 
abdomen, a right adrenal mass had been detected. Physical 
examination revealed moderate obesity (170 cm, 83 kg) and 
marked hypertension (180/115 to 230/120 mm Hg) but was 
otherwise normal. No heart murmurs were heard, and fun- 
doscopic and skin examination were unremarkable. Twenty- 
four hour blood pressure monitoring demonstrated a systolic 
mean of 170 mm Hg without diurnal rhythm. 
Serum electrolytes were normal except for mildly elevated 
corrected calcium levels of 2.6-2.8 mmol/L (2.0-2.5 
mmol/L) and a low potassium level of 3.3 mmol/L (3.5-5.5 
mmol/L). All other routine blood tests were within normal 
limits. Total 24-h urinary catecholamine measurements re- 
vealed markedly elevated concentrations of norepinephrine 
at 912 pg/24 h (cl00 pg/24 h), metanephrines at 4.5 mg/24 
h (<1.3 mg/24 h), and vanillylmandelic acid at 18 mg/24 h 
(<8 mg/24 h), whereas epinephrine and dopamine concen- 
trations were normal. Thyroid function tests revealed com- 
plete suppression of basal TSH at CO.03 mU/L (0.4-4.0 mU/ 
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L), elevated free T, concentration of 2.3 pg/L (0.8-1.8 pg/L), 
normal free T, concentration, and normal thyroglobulin and 
thyroid peroxidase autoantibody titers. Intact PTH level was 
markedly elevated at 160 rig/L (lo-55 rig/L). Measurements 
of pituitary hormones, calcitonin and carcinoembryonic an- 
tigen were all within normal limits. Thyroid hormone med- 
ication was discontinued, and antihypertensive treatment 
was started with phenoxybenzamine and titrated to 40 mg/ 
day until satisfactory control of blood pressure was achieved. 
A roentgenogram of the thorax was normal. ECG registration 
revealed normal sinus rhythmus at 60/min and was normal 
except for a slow R-wave progression in the anterior leads. 
Transthoracic echocardiography demonstrated left ventric- 
ular diameters at the upper range of normal and moderate 
mitral valve insufficiency. Magnetic resonance imaging 
(MRI) of the adrenal glands confirmed the presence of a 1.5 
X 2.5 cm right adrenal mass which, on T,-weighted images, 
failed to reveal high signal intensity. In search for a cate- 
cholamine-producing tumor at an extraadrenal site, 13’1- 
meta-iodobenzylguanidine (MIBG) whole body imaging 
was performed and revealed significant uptake medially in 
the mediastinum at the level of the 6th vertebral body (Fig. 
1). A CT scan of the mediastinum localized a well-demar- 
cated mass of 5 cm in diameter adjacent to the carina without 
obvious infiltration into neighboring structures. ECG-trig- 
gered MRI of the mediastinum located the mass on top of the 
left atrium and just below the carina. High signal intensity of 
this mass was demonstrated on T,-weighted MRI images 
(Fig. 2). No evidence of a parathyroid tumor was found on 
MRI studies extended to the neck and upper mediastinal 
area. Transesophageal echocardiography (TEE) demon- 
strated the mediastinal mass to be well-defined and situated 
on top of the pulmonary artery bifurcation just below the 
aortic arch (Fig. 3). On coronary angiography, blood supply 
of the mass was found to originate from both the circumflex 
and the right coronary artery. Cardiac paraganglioma coex- 
isting with a right adrenal gland incidentaloma and PTH- 
mediated hypercalcemia were diagnosed, and the patient 
was prepared for removal of the cardiac paraganglioma. 
Clinical Course 
Preoperatively, vigorous loading with iv fluids and phe- 
noxybenzamine (up to 200 mg/day) was continued until 
signs of orthostasis occurred, whereas blood pressure was 
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FIG. 1. 1311-MIBG whole body imaging demonstrates strong radio- 
nuclide uptake in the mediastinum (arrow). 
well controlled at 140/90 mm Hg. At surgery, the mass was 
found to infiltrate the left atrium from above and to require 
transsection of the ascending aorta and pulmonary artery 
with cardiopulmonary bypass for proper surgical exposure 
and tumor removal. The mass was totally resected, and atrio- 
plasty was performed using a pericardial patch. Histopa- 
thology revealed a highly vascularized tumor containing 
large polygonal chromaffin cells within a connective tissue 
capsule consistent with cardiac paraganglioma. The intra- 
and postoperative course was uncomplicated, and postop- 
erative blood pressure measurements and catecholamine ex- 
cretion returned to normal. Postoperative thyroid function 
tests were normal. In addition, serum concentrations for 
intact PTH had dropped to normal levels on repeated mea- 
surements, and corrected serum calcium concentrations fell 
to high normal levels (2.5-2.6 mmol/L). Pentagastrin-stim- 
ulated calcitonin levels were within normal limits. On fol- 
low-up visit 2 yr later, the patient felt entirely well, and her 
blood pressure measurements continued to be normal. Uri- 
nary catecholamine and metanephrine concentrations were 
normal, as were serum calcium and intact PTH levels. Pen- 
tagastrin-stimulated calcitonin levels were again within nor- 
FIG. 2. MRI images CT,-weighted) of the mediastinal mass (arrows) 
demonstrated in Fig. 1. High signal intensity of the mass is consistent 
with an extraadrenal pheochromocytoma. 
ma1 limits. A CT scan confirmed that the size of the right 
adrenal mass had remained unchanged. 
Discussion 
Location of extraadrenal pheochromocytoma may be 
highly variable, ranging from the pelvic floor up to the ca- 
rotid bodies. Extraabdominal location of pheochromocytoma 
is a rare clinical entity accounting for only 3% of all cases. 
Two thirds of these tumors are located in the thorax and the 
remainder in the neck region (1). The view that these tumors 
are more frequently malignant has been abandoned. How- 
ever, unusual clinical features frequently occur in patients 
with extraadrenal tumors and may include a mediastinal 
mass, upper airway obstruction, or gross hematuria and 
micturition-associated hypertensive crisis due to a tumor 
located in the bladder. Less than 50 cases of paragangliomas 
affecting the heart have been reported to date (2-4). Due to 
improved diagnostic localization techniques, cardiac pheo- 
chromocytomas are detected with increasing frequency. 
These tumors are predominantly located in close proximity 
to the atria1 structures, affecting the left atrium more com- 
monly than the right (4). Cardiac paragangliomas are 
thought to mainly arise from chromaffin cells adjacent to 
cardiac sympathetic fibers, or to be of ectopic origin (3). Early 
diagnosis and precise localization are mandatory because 
complete surgical resection may be curative in the majority 
of cases (4). However, in many instances, appropriate sur- 
gical management of cardiac paraganglioma may be only 
achieved with full thickness excision of the atria1 wall re- 
quiring cardiopulmonary bypass, followed by atria1 recon- 
struction using a pericardial patch (4). Intraoperative trans- 
section of the great vessels, coronary artery bypass, and even 
cardiac autotransplantation may be required in rare in- 
stances where excision would otherwise remain incomplete 
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FIG. 3. TEE demonstrates the location 
of the tumor (arrows) between the as- 
cending and descending aorta and ad- 
jacent to the pulmonary artery and the 
left cardiac auricle. 
(2-4). As demonstrated here, administration of incremental 
high doses of an a-adrenoreceptor blocking agent and gen- 
erous replacement of increased plasma volume requirements 
throughout the perioperative period may be essential to as- 
sure a good clinical outcome in these patients. 
The presence of the clinical triad of headache, sweating 
and palpitations in a hypertensive individual is considered 
to be highly predictive of pheochromocytoma (1). In addition 
to clearcut biochemical evidence of a catecholamine-produc- 
ing tumor, all of these features were present in our patient. 
Thus, localization rather than diagnosis was the challenge. 
Although the adrenal mass revealed by the outside CT scan 
was suspicious for an intraadrenal pheochromocytoma, 
there were also some hints in favor of an extraadrenal tumor 
location. First, biochemical testing revealed elevated norepi- 
nephrine levels but normal epinephrine levels. Although a 
majority of pheochromocytomas predominantly release nor- 
epinephrine, intraadrenal pheochromocytomas frequently 
also produce elevated levels of epinephrine. In fact, tumors 
that secrete only epinephrine tend to be familial and intraa- 
drenal in origin (1). Rarely, tumors may secrete dopamine, 
which does not cause hypertension but may be a clue to 
malignant pheochromocytoma (1). However, definitive di- 
agnosis of malignancy is still based on the finding of direct 
invasion or distant metastases and cannot be established on 
the basis of clinical, biochemical, or histologic criteria. Bio- 
chemical testing succeeds to establish the diagnosis in over 
95% of cases and largely depends on tumor size or activity, 
or both, but not on its location (11. It has been suggested that 
urinary norepinephrine excretion over 156 pg/24 h, urinary 
vanillylmandelic acid excretion over 11 mg/24 h, urinary 
total metanephrine excretion over 1.8 pg/24 h, or a sum of 
resting norepinephrine and epinephrine plasma levels of 
more than 2000 rig/L are diagnostic of pheochromocytoma 
(1,5). Sensitivities of elevated urinary and plasma levels of 
catecholamines or urinary metanephrine levels appear to be 
superior to that of vanillylmandelic acid excretion. For un- 
known reasons, sensitivity of biochemical tests in patients 
with pheochromocytomas occurring in the context of MEN 
2A are substantially lower, ranging from 86% for urinary 
norepinephrine levels to only 33% for plasma epinephrine 
levels (1). In addition, chromogranin A serum levels may be 
a complementary diagnostic tool in patients with normal 
creatinine clearance, especially because drugs commonly 
used to treat patients with pheochromocytoma do not inter- 
fere with its activity or detection (1). However, diagnostic 
specificity of this parameter approximates only 50% in pa- 
tients with a creatinine clearance of less than 80 ml/mm. If 
biochemical tests fail to unequivocally establish a diagnosis 
of pheochromocytoma and clinical suspicion persists, addi- 
tional dynamic tests such as clonidine suppression test may 
be required to discriminate between pheochromocytoma and 
other conditions causing increased sympathetic activity (1). 
A second clue to an extraadrenal location of the cate- 
cholamine-producing tumor came from MRI studies of the 
adrenal glands. These studies confirmed the presence and 
location of the mass previously detected on the outside CT 
scan but demonstrated low signal intensity of this tumor on 
T,-weighted images, a finding not usually consistent with 
pheochromocytoma. Diagnosis of pheochromocytoma rests 
with the presence of characteristic clinical signs and symp- 
toms and biochemical proof of excessive catecholamine pro- 
duction, followed by localization of its source. In the pres- 
ence of suggestive clinical and biochemical features, 
localization of an adrenal mass by computed tomography is 
usually straightforward. However, this widely used diag- 
nostic strategy cannot differentiate between adrenal pheo- 
chromocytoma and incidentaloma. Although of little rele- 
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Vance to the usual patient with pheochromocytoma, this 
strategy may be potentially catastrophic in the rare instance 
where a nonfunctioning adrenal mass happens to coincide 
with, and in fact, conceals an extraadrenal catecholamine- 
producing tumor. As demonstrated in this report, omission 
of additional imaging studies using either MRI imaging or 
MIBG scanning might not only have placed our patient at 
high risk for serious complications during surgical removal 
of her adrenal incidentaloma, but, in addition, would have 
subjected her to unnecessary surgery that left her actual 
problem untouched. 
Despite progress in imaging techniques, localization and 
treatment of paragangliomas has remained a challenge. Fol- 
lowing biochemical confirmation of suspected pheochromo- 
cytoma, a stepwise localization procedure should be fol- 
lowed for preoperative localization of the tumor site. 
Although CT and MRI appear to have similar sensitivities in 
localizing pheochromocytomas (98% and lOO%, respective- 
ly), specificities are substantially lower at 70% and 67%, 
respectively (1). In patients with increased catecholamine or 
catecholamine metabolite excretion and normal appearing 
adrenal glands on CT or MRI scans, the possibility of ex- 
traadrenal pheochromocytoma must be considered. Lesions 
within the chest may be visible by chest radiography and are 
usually obvious on CT scans. As a general caveat, CT scan- 
ning with iv contrast enhancement should be performed only 
after appropriate (Y- and /3-adrenoreceptorblockade for pre- 
vention of hypertensive crisis (1,5). The usefulness of CT or 
MRI scans in localizing extraadrenal catecholamine-produc- 
ing tumors has been compared in a small number of patients 
with paragangliomas (2-4). Given their noninvasive nature 
and wide availability, either imaging technique appears to 
represent a reasonable first step in the localization procedure, 
although MRI may be preferred, if available (6). MRI features 
suggesting paraganglioma are quite distinct and include 
high-signal intensity (hyperdense compared with liver) on 
T,-weighted images (6, 7). In addition to more sensitive and 
specific detection of paraganglioma, further advantages of 
MRI over CT may include more detailed topographic infor- 
mation pertinent to surgery, no interference with surgical 
clips, no need for iv contrast medium, and absence of radi- 
ation exposure, the latter making MRI the method of choice 
for detection of pheochromocytoma during pregnancy. 
If these techniques fail to localize an extraadrenal cate- 
cholamine-producing tumor, additional imaging procedures 
are required, including MIBG radionuclide scintigraphy, oc- 
treotide scanning, and thoracic and abdominal aortography 
that may permit detection of aorta-derived blood supply of 
extraadrenal tumors. MIBG scintigraphy, a functional rather 
than topographic test that allows scanning of the entire body, 
has proved to be superior to CT and MRI in localizing cardiac 
paragangliomas (3, 4, 7) and thus has recently assumed a 
prominent role in the localization of pheochromocytomas. 
The compound is taken up by pheochromocytomas, gangli- 
oneuromas, neuroblastomas, and other neural crest tumors 
as well as some carcinoids. Given its noninvasive nature, 
marked safety, and high specificity, MIBG scanning is now 
considered the gold standard for localization of small adre- 
nal lesions, bilateral adrenal lesions, metastatic deposits in 
patients with malignant adrenal tumors, and extraadrenal 
lesions, including cardiac paraganglioma (3,4,7). However, 
the high specificity of up to 100% of MIBG scintigraphy has 
to be balanced against its relatively low sensitivity (78%) (1). 
Although MIBG scanning may be considered optional in 
patients with biochemically proven pheochromocytoma and 
a documented adrenal mass, omission of an MIBG scan can 
lead to nondiagnosis of extraadrenal tumors or metastatic 
pheochromocytoma. In our patient, despite of diagnostic 
clinical and biochemical criteria and suggestive CT imaging 
studies, failure of the adrenal mass to display high signal 
intensity on T,-weighted MRI images led us to suspect an 
extraadrenal location and to perform MIBG radionuclide 
scanning. Further, octreotide scanning has become a prom- 
ising diagnostic tool that may provide additional informa- 
tion in the localization of an extraadrenal pheochromocy- 
toma. To date, however, the diagnostic accuracy and 
specificity of octreotide scanning in patients with pheochro- 
mocytoma have not been studied extensively (8). Further 
studies in larger numbers of patients will be required to 
assess the diagnostic value of octreotide scanning, and to 
compare it with MIBG scanning. 
The diagnostic value of TEE in localizing a paraganglioma 
has been disputed (3, 4). However, as demonstrated in our 
patient, TEE may provide significant additional information 
and details on topographic relationships that may assist the 
cardiothoracic surgeon in planning and conducting the sur- 
gical procedure. In addition, preoperative coronary angiog- 
raphy may provide the surgeon with important information 
about vascular supply of the tumor, thus preventing severe 
unexpected intraoperative hemorrhage during removal of 
well-vascularized tumors (2, 4). The diagnostic usefulness 
and definitive specificity of octreotide scanning both remain 
unclear because the number of patients studied was too small 
(8). Further studies, however, may be required to determine 
diagnostic accuracy of this promising diagnostic tool and to 
compare it with MIBG scanning. 
Hypercalcemia, as demonstrated in our patient, is an un- 
common but well recognized complication of pheochromo- 
cytoma. Etiologies of hypercalcemia may include coexisting 
primary hyperparathyroidism occurring as part of the MEN 
2A syndrome, catecholamine-induced release of PTH from 
parathyroid glands, ectopic production of PTH by the pheo- 
chromocytoma, catecholamine-mediated osteoclastic bone 
resorption, and the humoral hypercalcemia of malignancy 
syndromes mediated by PTH-related peptide (9). In our pa- 
tient, MEN 2A was ruled out by demonstration of normal 
pentagastrin-stimulated calcitonin levels, and by the absence 
of mutations in exons 10 and 11 of the RET protooncogene 
(10). Normalization of PTH levels and decline of serum cal- 
cium levels following successful removal of the paragangli- 
oma suggest, that, in our patient, preoperative hypercalce- 
mia was most likely due to either catecholamine-induced 
PTH release or ectopic PTH-production from the paragan- 
glioma, with or without catecholamine-mediated osteoclastic 
bone resorption. In addition, hyperthyroidism, which was 
initially present in our patient, may also have contributed to 
hypercalcemia and may have delayed diagnosis. Pheochro- 
mocytoma may closely mimic thyrotoxicosis in that tachy- 
cardia and hypermetabolism are common to both. Addi- 
tional similarities may include nervous irritability, 
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tremulousness, eye lid retraction, and excessive sweating. 
Thus, given this patient’s clinical presentation with palpita- 
tions and sweating in the presence of hypertension, hyper- 
thyroidism was included in the differential diagnosis. Dif- 
ferentiating these two entities may be particularly important 
because administration of a P-adrenoreceptor blocking agent 
to a patient with presumed hyperthyroidism may precipitate 
hypertensive crisis in case of a pheochromocytoma. This task 
may be further complicated by the fact that, in some patients 
with pheochromocytoma, norepinephrine-induced release 
of thyroid hormone may cause transient thyrotoxicosis (11). 
In this patient, however, hyperthyroxinemia was most likely 
due to ingestion of excessive amounts of levothyroxine, as 
thyroid function studies normalized preoperatively after 
thyroid hormone ingestion had been discontinued. Further, 
the presence of hypokalemia, hypertension, and an adrenal 
mass in this patient led us to consider primary hyperaldo- 
steronism as a differential diagnosis. However, hypernatre- 
mia and metabolic alkalosis, two other features of primary 
hyperaldosteronism. were absent. In addition, hypokalemia 
disappeared as soon as her treatment regimen was changed 
from furosemide to phenoxybenzamine, and postoperative 
serum potassium levels and blood pressure measurements 
were consistently within normal limits. Thus, administration 
of a loop diuretic agent without appropriate potassium re- 
placement most likely accounted for this patient’s hypoka- 
lemia. 
For practical purposes, we propose that either MR imaging 
or MIBG scintigraphy should be part of the preoperative 
localization strategy in all patients with biochemically 
proven pheochromocytoma. If MRI is not available or fails to 
display typical hyperintense signals on T,-weighted images, 
or if an extraadrenal catecholamine-producing tumor is sus- 
pected for other reasons, MIBG scintigraphy may be instru- 
mental in differentiating a nonfunctioning adrenal mass 
from a pheochromocytoma, correctly localizing the extraa- 
drenal tumor and avoiding the substantial risk and unpleas- 
ant scenario of performing surgery on an incidentaloma in a 
patient with an extraadrenal pheochromocytoma (7). Given 
its high specificity and diagnostic capacity, MIBG may even 
be advised as an important initial diagnostic tool for the 
detection of pheochromocytomas and extraadrenal paragan- 
gliomas. However, this recommendation may be limited by 
the fact that MIBG scintigraphy is expensive and not usually 
available even at major medical centers. In addition, approx- 
imately 10% of pheochromocytomas, most of which are lo- 
cated within the adrenal gland, may be missed due to low 
MIBG uptake or storage capacity (12). If MIBG scanning fails 
to localize the tumor despite biochemical evidence of pheo- 
chromocytoma, CT or MRI should be used for detection of 
intra- and extraadrenal tumors. Should all these techniques 
fail to reveal the location of a pheochromocytoma, then se- 
lective angiography, aortography, or catheterization of the 
inferior vena cava for detection of catecholamine gradients 
may be required, followed by CT or MRI reexamination of 
those regions (1, 5). Although frequently advised, shooting 
straight can do harm to some patients. The ever elusive 
paraganglioma continues to remind us of the opposite: the 
occasional need to stay away from the obvious. 
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